An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations
- 25 July 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Pharmacology
- Vol. 13 (8), 825-833
- https://doi.org/10.1080/17512433.2020.1796636
Abstract
Methylphenidate remains a first-line medication for treating ADHD in children and adults. However, its behavioral pharmacological similarities to methamphetamine and cocaine have historically created concern for its potential as a drug of abuse. In September 2019, the FDA published a docket requesting comments for the development of abuse deterrent formulations for CNS stimulants, emphasizing the abuse of methylphenidate as a public health concern. We conducted a narrative review of research on the clinical pharmacology, therapeutic efficacy, and abuse potential of methylphenidate. Several studies indicate that methylphenidate has at least some abuse potential. Methylphenidate, amphetamine, methamphetamine, and cocaine overlap in their subjective, reinforcing, and discriminative stimulus effects. Regardless, methylphenidate remains an efficacious treatment for ADHD in children and adults when properly adhered to, especially when paired with non-pharmacological treatments. The development of abuse deterrent formulations of methylphenidate is warranted.Keywords
This publication has 55 references indexed in Scilit:
- Pharmacological Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: Clinical StrategiesJournal of Central Nervous System Disease, 2012
- Methylphenidate produces selective enhancement of declarative memory consolidation in healthy volunteersPsychopharmacology, 2011
- Methylphenidate and μ opioid receptor interactions: A pharmacological target for prevention of stimulant abuseNeuropharmacology, 2011
- Comparison of the Behavioral and Cardiovascular Effects of Intranasal and Orald-Amphetamine in Healthy Human SubjectsThe Journal of Clinical Pharmacology, 2011
- Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity DisorderDrug Safety, 2010
- Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD)Psychopharmacology, 2008
- Discriminative Stimulus and Subject-Rated Effects of Methamphetamine, d-Amphetamine, Methylphenidate, and Triazolam in Methamphetamine-Trained HumansThe Journal of pharmacology and experimental therapeutics, 2008
- Reinforcing effects of stimulants in humans: Sensitivity of progressive-ratio schedules.Experimental and Clinical Psychopharmacology, 2008
- Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2European Journal of Pharmacology, 2007
- Behavioral and Cardiovascular Effects of Intravenous Methylphenidate in Normal Subjects and Cocaine AbusersEuropean Addiction Research, 1997